FTC Would Get Green Light To Go After Patent Thickets Under Bipartisan Senate Bill
Executive Summary
Legislation by Sens. Cornyn, R-TX, and Blumenthal, D-CT, in part reflects frustration over AbbVie’s tactics to preserve patent protection for Humira.
You may also be interested in...
Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement
Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.
House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.
From Pricing To Patents: Hearing Signals A Potential New Focus
Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.